The Patent Finder

Teva Pharmaceuticals Australia Pty Ltd.

Also on record
Records under this name other than the patents Teva Pharmaceuticals Australia Pty Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.

Back to Teva Pharmaceuticals Australia Pty Ltd.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,906,973Antibody Variants Transmigrating the Blood-Brain Barrier and Uses Thereof
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,725,052ANTI-PAR-2 Antibodies and Methods of Use Thereof
Formerly held
In force
 · High confidence
In forceHigh confidence
US 12,384,841ANTI-PAR-2 Antibodies and Methods of Use Thereof
Formerly held
In force
 · High confidence
In forceHigh confidence
US 12,358,980Compositions and Methods for Anti-Pacap Antibodies
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,253,591Combination of lenalidomide and polypeptide construct, and uses thereof
Lapsed on the fee record
Ended Feb 22, 2026 · USPTO record
Lapsed on the fee recordEnded Feb 22, 2026USPTO record
US 8,563,697Anti-IL-12/IL-23 antibodies
Lapsed on the fee record
Ended Oct 22, 2021 · USPTO record
Lapsed on the fee recordEnded Oct 22, 2021USPTO record
US 8,343,490Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
Lapsed on the fee record
Ended Jan 1, 2021 · USPTO record
Lapsed on the fee recordEnded Jan 1, 2021USPTO record
US 8,273,349Binding member which binds to both lewis-Y and lewis-B haptens, and its use for treating cancer
Lapsed on the fee record
Ended Sep 25, 2020 · USPTO record
Lapsed on the fee recordEnded Sep 25, 2020USPTO record
US 7,267,821Binding member which binds to both Lewisy and Lewisb haptens, and its use for treating cancer
Lapsed on the fee record
Ended Sep 11, 2019 · USPTO record
Lapsed on the fee recordEnded Sep 11, 2019USPTO record
US 9,127,057Anti-IL-23 heterodimer specific antibodies
Lapsed on the fee record
Ended Sep 8, 2019 · USPTO record
Lapsed on the fee recordEnded Sep 8, 2019USPTO record
10 of 15 patents shown.
Pro members see all 15.
Pro members: see all 15 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited